Opus Genetics, Inc. IRD
4.76
(0.11)
(2.26%)
as of 25 Sep
- Market cap
- $405.2M
- P/E
- 0.0×
Follow IRD
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(338.75%) | (449.36%) | 524.65% | (4,796.52%) | |
| (178.28%) | (113.86%) | (186.04%) | (163.50%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(969.48%) | (116.79%) | (186.14%) | (126.21%) | |
Average Days of Receivables |
72.74 | 51.29 | 52.73 | 38.55 | |
Free Cash Flow per Share |
(0.47) | (0.57) | (0.45) | (0.43) | |
Free Cash Flow |
(32.86) | (35.25) | (38.99) | (40.67) | |
Piotroski F-Score |
2.00 | 4.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(86.81%) | (58.33%) | (276.05%) | (36.72%) | |
Accounts Receivable Turnover |
6.13 | 5.11 | 4.98 | 4.44 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
378.72% | 217.05% | 279.03% | 391.85% | |
Selling, General and Administrative Expense of Revenue |
166.68% | 154.85% | 180.10% | 221.62% | |
Share Based Compensation of Revenue |
23.37% | 23.94% | 32.96% | 45.26% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.48 | 0.71 | 0.36 | 0.38 | |
Depreciation/Fixed assets |
0.24 | 0.27 | 0.28 | 0.31 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.21 | 0.23 | 0.14 | 0.10 | |
Operating CF per Share |
(0.47) | (0.57) | (0.45) | (0.43) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(466.09%) | (349.33%) | (892.36%) | (1,091.82%) |
Columns are period end dates